Artificial intelligence's role in day-to-day patient care continues to grow. What should health systems and cardiology departments be thinking about as they shop for new technologies?

Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.

Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.

Australia-based Artrya Limited says its AI-enabled Salix Coronary Plaque module offers near real-time, point-of-care CCTA assessment and management of coronary artery disease. 

A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more. 

Most patients are first diagnosed with heart failure in an emergency room or hospital, when their symptoms are already severe. This advanced algorithm could change all that by opening up screening to many more patients. 

Ultromics plans to use the new funds to help expand its presence throughout the United States. In addition, the company is focused on developing additional AI-enabled software offerings.